• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

1. What Sunlenca is and what it is used for
2. What you need to know before you are given Sunlenca
3. How Sunlenca is given
4. Possible side effects
5. How to store Sunlenca
6. Contents of the pack and other information

• If you are allergic to lenacapavir or any of the other ingredients of this medicine (listed in section 6)
• If you are taking any of these medicines:
  • rifampicin, used to treat some bacterial infections such as tuberculosis
  • carbamazepine, phenytoin, used to prevent seizures
  • St. John’s wort (Hypericum perforatum), a herbal remedy used for depression and anxiety

• Do not receive Sunlenca and tell your doctor immediately if you think this applies to you.

Talk to your doctor before using Sunlenca

• Talk to your doctor or pharmacist if you have ever had severe liver disease, or if tests have shown problems with your liver. Your doctor will carefully consider whether to treat you with Sunlenca.

Once you start using Sunlenca, look out for:

• Signs of inflammation or infection.

• If you notice any of these symptoms, tell your doctor immediately. For more information, see section 4, Possible side effects.

It is important that you attend your planned appointments to receive your Sunlenca injection, to control your HIV infection, and to stop your illness from getting worse. Talk to your doctor if you are thinking about stopping treatment. If you are late receiving your Sunlenca injection, or if you stop receiving Sunlenca, your will need to take other medicines to treat your HIV infection and to reduce the risk of developing viral resistance.

Do not give this medicine to children under 18 years of age. The use of Sunlenca in patients aged under 18 has not yet been studied, so it is not known how safe and effective the medicine is in that age group.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Sunlenca may interact with other medicines. This may keep Sunlenca or other medicines from working properly, or may make side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.

• rifampicin, used to treat some bacterial infections, such as tuberculosis
• carbamazepine, phenytoin, used to prevent seizures
  
• St. John’s wort (Hypericum perforatum), a herbal remedy used for depression and anxiety

• If you are taking any of these medicines, do not receive Sunlenca injection and tell your doctor immediately.

• antibiotics containing:
  • rifabutin
• anticonvulsants used to treat epilepsy and prevent seizures (fits), containing:
  • oxcarbazepine or phenobarbital
• medicines used to treat HIV, containing:
  • atazanavir/cobicistat, efavirenz, nevirapine, tipranavir/ritonavir or etravirine
• medicines used to treat migraine headache, containing:
  • dihydroergotamine or ergotamine
• medicine used to treat impotence and pulmonary hypertension, containing:
  • sildenafil or tadalafil
• medicine used to treat impotence, containing:
  • vardenafil
• corticosteroids (also known as ‘steroids’) taken orally or given by injection used to treat allergies, inflammatory bowel diseases, and other various illnesses involving inflammations in your body, containing:
  • dexamethasone or hydrocortisone/cortisone
• medicines used to lower cholesterol, containing:
  • lovastatin or simvastatin
• antiarrhythmics used to treat heart problems, containing:
  • digoxin
• medicines used to help you sleep, containing:
  • midazolam or triazolam.
• anticoagulants used to prevent and treat blood clots, containing:
  • rivaroxaban, dabigatran or edoxaban

• Tell your doctor if you are taking any of these medicines or if you start taking any of these medicines during treatment with Sunlenca. Do not stop any treatment without contacting your doctor.

Sunlenca is a long-acting medicine. If after talking to your doctor you decide to stop your treatment or switch to another, you should know low levels of lenacapavir (the active substance in Sunlenca) can remain in your system for many months after your last injection. These low remaining levels should not affect other antiretroviral medicines that you take afterwards to treat your HIV infection. Some other medicines however may be affected by the low levels of lenacapavir in your system if you take them within 9 months after your last Sunlenca injection. You should check with your doctor if such medicines are safe for you to take after you stop treatment with Sunlenca.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

As a precautionary measure you should avoid the use of Sunlenca during pregnancy unless your doctor tells you otherwise.

Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby through breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.

Sunlenca is not expected to have any effect on your ability to drive or use machines.

This medicine contains less than 1 mmol sodium (23 mg) per injection, that is to say essentially ‘sodium-free’.

Your doctor or a nurse will give this medicine to you, so it is unlikely that you will be given too much. If you are worried, tell the doctor or a nurse.

• It is important that you attend your planned appointments every 6 months to receive your injections of Sunlenca. This will help to control your HIV infection and to stop your illness from getting worse.
• If you think you will not be able to attend your appointment for your injections , call your doctor as soon as possible to discuss your treatment options.
  

If you miss or vomit the tablets, refer to the package leaflet for Sunlenca tablets.

Do not stop receiving Sunlenca without talking to your doctor. Keep receiving Sunlenca injections for as long as your doctor recommends. Stopping Sunlenca can seriously affect how future HIV treatments work.

• Talk to your doctor if you want to stop receiving Sunlenca injections.

• Any signs of inflammation or infection. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after HIV treatment is started. It is thought that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
• Autoimmune disorders, when the immune system attacks healthy body tissue, may also occur after you start taking medicines for HIV infection. Autoimmune disorders may occur many months after the start of treatment. Look out for any symptoms of infection or other symptoms such as:
  • muscle weakness
  • weakness beginning in the hands and feet and moving up towards the trunk of the body
  • palpitations, tremor or hyperactivity

• If you notice these or any symptoms of inflammation or infection, tell your doctor immediately.

Very common side effects

(may affect more than 1 in 10 people)

• Reactions where Sunlenca is injected.
  Symptoms may include:
  • pain and discomfort
  • a hardened mass or lump
  • inflammatory reaction such as redness, itching, and swelling

Common side effects

(may affect up to 1 in 10 people)

• Feeling sick (nausea)

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

The active substance is lenacapavir. Each single-use vial contains 463.5 mg of lenacapavir.

The other ingredients are

Macrogol (E1521), water for injections.

Sunlenca solution for injection (injection) is a clear, yellow to brown solution with no visible particles. Sunlenca comes in two glass vials, each containing 1.5 ml of solution for injection. These vials are included in a dosing kit also containing 2 vial access devices (a device that will allow your doctor or a nurse to withdraw Sunlenca from the vial), 2 disposable syringes and 2 injection needles.

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: